Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Eckert & Ziegler Strahlen- und Medizintechnik

BATS-CHIXE:EUZd
Snowflake Description

Flawless balance sheet with solid track record and pays a dividend.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EUZd
BATS-CHIXE
€655M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. The last earnings update was 147 days ago. More info.


Add to Portfolio Compare Print
  • Eckert & Ziegler Strahlen- und Medizintechnik has significant price volatility in the past 3 months.
EUZd Share Price and Events
7 Day Returns
-11%
BATS-CHIXE:EUZd
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
46.7%
BATS-CHIXE:EUZd
-0.3%
GB Medical Equipment
-23.6%
GB Market
EUZd Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eckert & Ziegler Strahlen- und Medizintechnik (EUZd) -11% -16.6% -33.9% 46.7% 394.4% 486.1%
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • EUZd outperformed the Medical Equipment industry which returned -0.3% over the past year.
  • EUZd outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
EUZd
Industry
5yr Volatility vs Market

EUZd Value

 Is Eckert & Ziegler Strahlen- und Medizintechnik undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Eckert & Ziegler Strahlen- und Medizintechnik to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Eckert & Ziegler Strahlen- und Medizintechnik.

BATS-CHIXE:EUZd Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:EUZd
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 30%) (2.82%))
0.882
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.88
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.882 * 5.44%)
5.33%

Discounted Cash Flow Calculation for BATS-CHIXE:EUZd using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Eckert & Ziegler Strahlen- und Medizintechnik is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:EUZd DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 5.33%)
2020 21.10 Analyst x1 20.03
2021 15.60 Analyst x1 14.06
2022 30.20 Analyst x1 25.85
2023 34.56 Est @ 14.45% 28.08
2024 38.12 Est @ 10.27% 29.40
2025 40.92 Est @ 7.35% 29.97
2026 43.09 Est @ 5.3% 29.96
2027 44.76 Est @ 3.87% 29.55
2028 46.04 Est @ 2.87% 28.86
2029 47.04 Est @ 2.17% 27.99
Present value of next 10 years cash flows €263.00
BATS-CHIXE:EUZd DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €47.04 × (1 + 0.53%) ÷ (5.33% – 0.53%)
€985.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €985.75 ÷ (1 + 5.33%)10
€586.63
BATS-CHIXE:EUZd Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €263.00 + €586.63
€849.63
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €849.63 / 5.15
€165.06
BATS-CHIXE:EUZd Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:EUZd represents 1.00158x of XTRA:EUZ
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.00158x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 165.06 x 1.00158
€165.32
Value per share (EUR) From above. €165.32
Current discount Discount to share price of €126.30
= -1 x (€126.30 - €165.32) / €165.32
23.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Eckert & Ziegler Strahlen- und Medizintechnik is available for.
Intrinsic value
24%
Share price is €126.3 vs Future cash flow value of €165.32
Current Discount Checks
For Eckert & Ziegler Strahlen- und Medizintechnik to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Eckert & Ziegler Strahlen- und Medizintechnik's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Eckert & Ziegler Strahlen- und Medizintechnik's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eckert & Ziegler Strahlen- und Medizintechnik's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eckert & Ziegler Strahlen- und Medizintechnik's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:EUZd PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in EUR €4.28
XTRA:EUZ Share Price ** XTRA (2020-04-06) in EUR €126.1
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eckert & Ziegler Strahlen- und Medizintechnik.

BATS-CHIXE:EUZd PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:EUZ Share Price ÷ EPS (both in EUR)

= 126.1 ÷ 4.28

29.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eckert & Ziegler Strahlen- und Medizintechnik is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Eckert & Ziegler Strahlen- und Medizintechnik is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Eckert & Ziegler Strahlen- und Medizintechnik's expected growth come at a high price?
Raw Data
BATS-CHIXE:EUZd PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 29.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
9.3%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:EUZd PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 29.46x ÷ 9.3%

3.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eckert & Ziegler Strahlen- und Medizintechnik is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Eckert & Ziegler Strahlen- und Medizintechnik's assets?
Raw Data
BATS-CHIXE:EUZd PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in EUR €26.43
XTRA:EUZ Share Price * XTRA (2020-04-06) in EUR €126.1
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:EUZd PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:EUZ Share Price ÷ Book Value per Share (both in EUR)

= 126.1 ÷ 26.43

4.77x

* Primary Listing of Eckert & Ziegler Strahlen- und Medizintechnik.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eckert & Ziegler Strahlen- und Medizintechnik is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Eckert & Ziegler Strahlen- und Medizintechnik's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Eckert & Ziegler Strahlen- und Medizintechnik has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EUZd Future Performance

 How is Eckert & Ziegler Strahlen- und Medizintechnik expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eckert & Ziegler Strahlen- und Medizintechnik expected to grow at an attractive rate?
  • Eckert & Ziegler Strahlen- und Medizintechnik's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Eckert & Ziegler Strahlen- und Medizintechnik's earnings growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.
  • Eckert & Ziegler Strahlen- und Medizintechnik's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:EUZd Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:EUZd Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 9.3%
BATS-CHIXE:EUZd Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 5.8%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:EUZd Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:EUZd Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 215 37 30 1
2021-12-31 197 31 26 1
2020-12-31 178 28 22 1
2020-04-07
2019-12-31 180 23 23 1
BATS-CHIXE:EUZd Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-09-30 178 37 22
2019-06-30 177 30 21
2019-03-31 177 28 20
2018-12-31 169 21 16
2018-09-30 162 20 16
2018-06-30 155 21 14
2018-03-31 142 23 11
2017-12-31 139 27 12
2017-09-30 131 31 11
2017-06-30 124 30 11
2017-03-31 117 24 11
2016-12-31 120 20 10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Eckert & Ziegler Strahlen- und Medizintechnik's earnings are expected to grow by 9.3% yearly, however this is not considered high growth (20% yearly).
  • Eckert & Ziegler Strahlen- und Medizintechnik's revenue is expected to grow by 5.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:EUZd Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Eckert & Ziegler Strahlen- und Medizintechnik Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:EUZd Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 5.80 5.80 5.80 1.00
2021-12-31 4.98 4.98 4.98 1.00
2020-12-31 4.29 4.29 4.29 1.00
2020-04-07
2019-12-31 4.38 4.38 4.38 1.00
BATS-CHIXE:EUZd Past Financials Data
Date (Data in EUR Millions) EPS *
2019-09-30 4.28
2019-06-30 4.06
2019-03-31 3.82
2018-12-31 3.12
2018-09-30 2.97
2018-06-30 2.58
2018-03-31 2.04
2017-12-31 2.19
2017-09-30 2.15
2017-06-30 2.15
2017-03-31 2.03
2016-12-31 1.93

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Eckert & Ziegler Strahlen- und Medizintechnik is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Eckert & Ziegler Strahlen- und Medizintechnik's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eckert & Ziegler Strahlen- und Medizintechnik has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EUZd Past Performance

  How has Eckert & Ziegler Strahlen- und Medizintechnik performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eckert & Ziegler Strahlen- und Medizintechnik's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eckert & Ziegler Strahlen- und Medizintechnik's year on year earnings growth rate has been positive over the past 5 years.
  • Eckert & Ziegler Strahlen- und Medizintechnik's 1-year earnings growth exceeds its 5-year average (41.1% vs 17.9%)
  • Eckert & Ziegler Strahlen- und Medizintechnik's earnings growth has exceeded the GB Medical Equipment industry average in the past year (41.1% vs -9.5%).
Earnings and Revenue History
Eckert & Ziegler Strahlen- und Medizintechnik's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eckert & Ziegler Strahlen- und Medizintechnik Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:EUZd Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 178.10 21.89 52.47
2019-06-30 176.73 20.70 53.16
2019-03-31 176.52 19.60 52.04
2018-12-31 168.71 16.13 50.20
2018-09-30 162.02 15.51 47.18
2018-06-30 154.84 13.60 44.52
2018-03-31 141.57 10.79 43.97
2017-12-31 138.63 11.60 43.86
2017-09-30 130.81 11.38 43.08
2017-06-30 123.78 11.35 43.84
2017-03-31 116.86 10.71 41.23
2016-12-31 119.87 10.21 42.82
2016-09-30 126.77 9.36 45.64
2016-06-30 131.86 8.89 46.95
2016-03-31 141.68 11.32 51.42
2015-12-31 139.75 11.67 51.71
2015-09-30 137.16 11.47 51.33
2015-06-30 134.12 11.67 50.93
2015-03-31 130.44 8.18 49.44
2014-12-31 127.26 6.78 48.47
2014-09-30 123.56 8.36 46.71 -2.84
2014-06-30 123.76 8.32 46.28 -1.96
2014-03-31 121.34 9.42 45.64 -0.91
2013-12-31 117.14 9.04 44.48
2013-09-30 118.39 9.44 44.38 3.97
2013-06-30 117.42 8.83 43.93 3.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Eckert & Ziegler Strahlen- und Medizintechnik has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Eckert & Ziegler Strahlen- und Medizintechnik used its assets more efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Eckert & Ziegler Strahlen- und Medizintechnik has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Eckert & Ziegler Strahlen- und Medizintechnik's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eckert & Ziegler Strahlen- und Medizintechnik has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EUZd Health

 How is Eckert & Ziegler Strahlen- und Medizintechnik's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eckert & Ziegler Strahlen- und Medizintechnik's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eckert & Ziegler Strahlen- und Medizintechnik is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eckert & Ziegler Strahlen- und Medizintechnik's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Eckert & Ziegler Strahlen- und Medizintechnik's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 7.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eckert & Ziegler Strahlen- und Medizintechnik Company Filings, last reported 6 months ago.

BATS-CHIXE:EUZd Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 137.28 18.49 70.75
2019-06-30 130.67 19.16 57.09
2019-03-31 130.89 19.56 60.05
2018-12-31 123.88 0.16 54.19
2018-09-30 120.57 0.52 49.05
2018-06-30 118.46 1.00 46.63
2018-03-31 118.79 1.60 53.46
2017-12-31 117.52 1.95 57.71
2017-09-30 115.11 2.81 52.95
2017-06-30 114.02 2.80 42.79
2017-03-31 113.52 8.37 36.75
2016-12-31 110.08 12.13 36.57
2016-09-30 108.29 12.94 32.15
2016-06-30 105.65 14.00 25.86
2016-03-31 105.56 14.02 29.74
2015-12-31 104.67 16.17 31.47
2015-09-30 101.67 16.07 29.08
2015-06-30 100.95 17.46 19.56
2015-03-31 101.16 18.65 22.47
2014-12-31 94.49 19.57 21.82
2014-09-30 94.74 20.38 20.19
2014-06-30 90.80 20.57 18.84
2014-03-31 92.25 21.75 25.16
2013-12-31 90.27 23.44 29.44
2013-09-30 87.27 20.28 27.94
2013-06-30 86.00 16.87 21.60
  • Eckert & Ziegler Strahlen- und Medizintechnik's level of debt (13.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (21.5% vs 13.5% today).
  • Debt is well covered by operating cash flow (198.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 36.2x coverage).
X
Financial health checks
We assess Eckert & Ziegler Strahlen- und Medizintechnik's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eckert & Ziegler Strahlen- und Medizintechnik has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EUZd Dividends

 What is Eckert & Ziegler Strahlen- und Medizintechnik's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.35%
Current annual income from Eckert & Ziegler Strahlen- und Medizintechnik dividends. Estimated to be 1.33% next year.
If you bought €2,000 of Eckert & Ziegler Strahlen- und Medizintechnik shares you are expected to receive €27 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Eckert & Ziegler Strahlen- und Medizintechnik's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Eckert & Ziegler Strahlen- und Medizintechnik's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Upcoming dividend payment

Purchase Eckert & Ziegler Strahlen- und Medizintechnik before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:EUZd Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:EUZd Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 1.93 1.00
2021-12-31 1.66 1.00
2020-12-31 1.43 1.00
2020-04-07
2019-12-31 1.46 1.00
BATS-CHIXE:EUZd Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-03-27 1.700 1.269
2019-05-29 1.200 0.833
2018-03-29 0.800 1.532
2018-03-22 0.800 2.320
2018-03-08 0.600 1.672
2017-03-23 0.600 1.780
2016-03-23 0.600 2.708
2015-03-26 0.600 2.973
2014-03-27 0.600 2.677
2014-01-15 0.600 2.375
2013-03-26 0.600 2.194
2013-01-15 0.600 2.283
2012-03-26 0.600 2.646
2011-03-23 0.600 2.361
2010-03-01 0.450 1.859
2009-04-30 0.300 1.919

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Eckert & Ziegler Strahlen- und Medizintechnik's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.6x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3x coverage).
X
Income/ dividend checks
We assess Eckert & Ziegler Strahlen- und Medizintechnik's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eckert & Ziegler Strahlen- und Medizintechnik afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eckert & Ziegler Strahlen- und Medizintechnik has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EUZd Management

 What is the CEO of Eckert & Ziegler Strahlen- und Medizintechnik's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andreas Eckert
COMPENSATION €722,895
AGE 59
CEO Bio

Dr. Andreas Eckert, PhD, is the Founder and Managing Partner of ELSA Eckert Life Science Accelerator GmbH. Dr. Exkert is the Founder of Eckert & Ziegler Strahlen & Medizintechnik AG and serves as its Chief Executive Officer. Dr. Eckertf is Chairman of the Executive Board of Eckert & Ziegler Strahlen & Medizintechnik AG. He is a Co-founder of Glycotope. Dr. Eckert serves as Managing Director at Eckert Wagniskapital und Frühphasenfinanzierung GmbH. Dr. Eckert is the Founder of Eckert & Ziegler BEBIG GmbH in 1992 and serves as its Vice President of Sales & Marketing. Dr. Eckert served as Chief Executive Officer of Eckert & Ziegler BEBIG GmbH. Dr. Eckert started his career as a Theatre Journalist. Subsequently, he worked for the United Nations at its headquarters in New York and was later stationed in Africa, Asia and Latin America. He has been a Member of the Executive Board at Eckert & Ziegler Strahlen & Medizintechnik AG since July 3, 1997. He serves as Chairman of the Board of Directors at Eckert & Ziegler BEBIG GmbH. Dr. Eckert serves as Chairman of Eckert & Ziegler Bebig. Dr. Eckert serves as the Chairman of the Supervisory Board at Berlin Partner für Wirtschaft und Technologie GmbH. Dr. Eckert serves as the Chairman of board at Eckert & Ziegler BEBIG S.A. and has been its Director since March 8, 2008. He served as Chairman of Eckert & Ziegler BEBIG S.A. since March 8, 2008 until May 2009 and served as its Director since March 8, 2008. He served as Executive Board Chairman of Eckert & Ziegler BEBIG S.A. He has been a Director of Glycotope GmbH since April 2, 2017. Dr. Eckert serves as a Member of Advisory Committee at eCAPITAL entrepreneurial Partners AG.

CEO Compensation
  • Andreas's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Andreas's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Eckert & Ziegler Strahlen- und Medizintechnik management team in years:

4.8
Average Tenure
55
Average Age
  • The tenure for the Eckert & Ziegler Strahlen- und Medizintechnik management team is about average.
Management Team

Andreas Eckert

TITLE
Chairman of Executive Board & CEO
COMPENSATION
€723K
AGE
59

Harald Hasselmann

TITLE
Head of Radiation Therapy Segment & Member of the Executive Board
COMPENSATION
€347K
AGE
52
TENURE
3.3 yrs

Lutz Helmke

TITLE
Member of Executive Board
COMPENSATION
€221K
AGE
58
TENURE
1.6 yrs

Frank Yeager

TITLE
Head of Isotope Products Segment

Gunnar Mann

TITLE
Head of Intragroup Services
AGE
52
TENURE
8.3 yrs

Joe Hathcock

TITLE
Vice President of Eckert & Ziegler Isotope Products Inc

Ivan Simmer

TITLE
Managing Director of Eckert & Ziegler Cesio s.r.o.
TENURE
6.3 yrs
Board of Directors Tenure

Average tenure and age of the Eckert & Ziegler Strahlen- und Medizintechnik board of directors in years:

2
Average Tenure
66
Average Age
  • The average tenure for the Eckert & Ziegler Strahlen- und Medizintechnik board of directors is less than 3 years, this suggests a new board.
Board of Directors

Wolfgang Maennig

TITLE
Chairman of Supervisory Board
COMPENSATION
€35K
AGE
59
TENURE
6.9 yrs

Helmut Grothe

TITLE
Deputy Chairman of the Supervisory Board
COMPENSATION
€26K
TENURE
2.8 yrs

Frank Perschmann

TITLE
Member of Supervisory Board
COMPENSATION
€5K
AGE
66
TENURE
0.9 yrs

Edgar Löffler

TITLE
Member of Supervisory Board
COMPENSATION
€291K
AGE
66
TENURE
1.3 yrs

Albert Rupprecht

TITLE
Member of Supervisory Board
COMPENSATION
€17K
TENURE
2.9 yrs

Jutta Ludwig

TITLE
Member of Supervisory Board
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Eckert & Ziegler Strahlen- und Medizintechnik's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eckert & Ziegler Strahlen- und Medizintechnik has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EUZd News

Simply Wall St News

EUZd Company Info

Description

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: Radiation Therapy, Radiopharma, and Isotope Products. The Radiation Therapy segment develops, manufactures, markets, and sells radioactive products for cancer therapy. This segment offers small radioactive implants for the treatment of prostate cancer seeds; and tumor radiation devices and eye applicators. This segment’s products and equipment are used by oncologists, radiotherapists, urologists, ophthalmologists, and medical physicists. The Radiopharma segment operates in the field of molecular imaging and nuclear medicine; and supplies various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment provides products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. The Isotope Products segment offers sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. It also provides custom and one-off design and manufacturing services. In addition, the company offers services for collection, recycling, and disposal of sealed radioactive sources and low activity isotope related waste from hospitals, research institutes, and industries. Eckert & Ziegler Strahlen- und Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.

Details
Name: Eckert & Ziegler Strahlen- und Medizintechnik AG
EUZd
Exchange: BATS-CHIXE
Founded: 1992
€654,764,925
5,147,523
Website: http://www.ezag.com
Address: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Strasse 10,
Berlin,
13125,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA EUZ Ordinary Shares XETRA Trading Platform DE EUR 25. May 1999
DB EUZ Ordinary Shares Deutsche Boerse AG DE EUR 25. May 1999
LSE 0NZY Ordinary Shares London Stock Exchange GB EUR 25. May 1999
BATS-CHIXE EUZd Ordinary Shares BATS 'Chi-X Europe' GB EUR 25. May 1999
ETLX EUZ Ordinary Shares Eurotlx IT EUR 25. May 1999
Number of employees
Current staff
Staff numbers
812
Eckert & Ziegler Strahlen- und Medizintechnik employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 19:45
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.